| P50 | author | Daisy Ng-Mak | Q88267481 |
| P2093 | author name string | Antony Loebel | |
| | Jonathan M Meyer | |
| | Krithika Rajagopalan | |
| | Chien-Chia Chuang | |
| P2860 | cites work | Side effects of atypical antipsychotics: a brief overview | Q24642721 |
| | Lurasidone for the treatment of bipolar depression: an evidence-based review | Q26796437 |
| | Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 |
| | Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis | Q28293647 |
| | Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review | Q33988376 |
| | Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study | Q34073723 |
| | Adverse effects of antipsychotic medications | Q34100832 |
| | Weight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database | Q34337229 |
| | Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases | Q34439990 |
| | Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia | Q34486175 |
| | Trends in Obesity Among Adults in the United States, 2005 to 2014. | Q34530004 |
| | Metabolic considerations in the use of antipsychotic medications: a review of recent evidence | Q34575009 |
| | Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis | Q34641561 |
| | Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. | Q34764122 |
| | The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial | Q34807210 |
| | Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis | Q35566086 |
| | Savings in Medical Expenditures Associated with Reductions in Body Mass Index Among US Adults with Obesity, by Diabetes Status | Q35801517 |
| | Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia | Q35855167 |
| | Obesity in schizophrenia: what can be done about it? | Q36044597 |
| | Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity | Q36545178 |
| | Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia | Q36670942 |
| | Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial | Q36756154 |
| | Health status of individuals with serious mental illness | Q37075921 |
| | A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP) | Q37172973 |
| | Weight gain in antipsychotic-naive patients: a review and meta-analysis | Q37572952 |
| | Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic | Q37815561 |
| | Efficacy of metformin for prevention of weight gain in psychiatric populations: a review | Q37943231 |
| | Lurasidone in schizophrenia: new information about dosage and place in therapy | Q38045797 |
| | Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study | Q38454983 |
| | Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis. | Q38545272 |
| | Prevalence of Obesity Among Adults and Youth: United States, 2011-2014. | Q40246125 |
| | Effect of degree of weight loss on health benefits | Q40958693 |
| | Prevalence of obesity and weight change during treatment in patients with bipolar I disorder | Q43642752 |
| | Obesity as a correlate of outcome in patients with bipolar I disorder | Q44265285 |
| | Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. | Q46037113 |
| | Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians | Q46714706 |
| | Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone | Q47279555 |
| | Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials | Q47427837 |
| | Relationship between metabolic syndrome and cognition in patients with schizophrenia | Q49057470 |
| | Non-adherence to antipsychotic medication regimens: associations with resource use and costs. | Q50744733 |
| | The prevalence of metabolic syndrome in patients with bipolar disorder. | Q51467623 |
| | Obesity as a risk factor for antipsychotic noncompliance. | Q51944586 |
| | Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder. | Q53159774 |
| | The potential association between obesity and bipolar disorder: A meta-analysis | Q57772992 |
| | Correlates of overweight and obesity in 644 patients with bipolar disorder | Q60646356 |
| | Consensus development conference on antipsychotic drugs and obesity and diabetes | Q94355363 |
| P4510 | describes a project that uses | electronic health records | Q10871684 |
| P921 | main subject | electronic health records | Q10871684 |
| P304 | page(s) | 36 | |
| P577 | publication date | 2017-10-17 | |
| P1433 | published in | Annals of General Psychiatry | Q15764563 |
| P1476 | title | Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records | |
| P478 | volume | 16 | |